Tirzepatide and retatrutide represent the current and next generation of incretin-based obesity therapy. Tirzepatide broke new ground as the first dual agonist. Retatrutide adds a third receptor — glucagon — to potentially push weight loss even further. The question is whether the additional mechanism justifies the leap to an investigational drug.
How They Work
Tirzepatide is a dual agonist targeting GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GLP-1 component reduces appetite, slows gastric emptying, and improves glucose regulation. The GIP component enhances the GLP-1 effect on appetite suppression while also targeting white adipose tissue for improved fat metabolism and insulin sensitivity. GIP's anti-emetic properties may also contribute to tirzepatide's better tolerability compared to GLP-1-only drugs. It is engineered with a fatty acid side chain for albumin binding, providing a half-life of approximately 5 days.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. It incorporates all of tirzepatide's mechanisms (appetite suppression, improved insulin sensitivity, fat metabolism) and adds glucagon receptor agonism. Glucagon activation increases hepatic glucose output (managed by the concurrent GLP-1/GIP activity), drives thermogenesis (increased energy expenditure), promotes lipolysis and fatty acid oxidation, and may reduce hepatic steatosis. This triple mechanism creates a more comprehensive metabolic profile than dual agonism alone. Developed by Eli Lilly, retatrutide has a half-life of approximately 6 days.
What the Research Shows
Tirzepatide has extensive clinical data across the SURMOUNT (obesity) and SURPASS (diabetes) programs. SURMOUNT-1 demonstrated 20.9% average weight loss at 72 weeks with the 15mg dose, with over 50% of participants losing more than 20% of body weight. SURPASS-2 showed superiority over semaglutide for both HbA1c reduction and weight loss. Post-marketing real-world data continues to support its clinical trial efficacy.
Retatrutide Phase 2 data is striking. At the highest dose (12mg), participants lost an average of 24.2% of body weight at 48 weeks — the most weight loss ever reported in an obesity drug trial at that time. Dose-response was clear, with increasing efficacy at higher doses. Phase 3 trials are underway, but results are not yet available. Importantly, the 48-week Phase 2 endpoint is shorter than tirzepatide's 72-week SURMOUNT data, making direct comparison imprecise.
Side Effects and Tolerability
Tirzepatide's side-effect profile is well-characterized: nausea, diarrhea, constipation, and fatigue are the most common GI adverse events. These typically peak during dose escalation and improve with continued use. GIP's anti-emetic properties may contribute to better tolerability compared to GLP-1-only drugs. Serious adverse events are rare.
Retatrutide shares the GI side-effect profile of tirzepatide (nausea, diarrhea, vomiting) but introduces additional considerations from glucagon receptor agonism. Glucagon can increase heart rate, and Phase 2 data showed modest heart rate elevation in the highest dose groups. Glucagon also opposes insulin's glucose-lowering effects, though the concurrent GLP-1/GIP activity appeared to maintain glycemic control. Long-term safety data is not yet available.
Availability and Practical Considerations
Tirzepatide is widely available. It is FDA approved as Zepbound (obesity) and Mounjaro (Type 2 diabetes) and accessible through compounding pharmacies at lower cost. Prescribing, titration, and monitoring protocols are well-established.
Retatrutide is not commercially available. Access is limited to clinical trial enrollment. There is no established prescribing protocol, compounding availability, or insurance coverage. If Phase 3 trials are successful, FDA submission and approval could take several years.
How to Choose
Choose Tirzepatide if: you want a proven, FDA-approved, commercially available dual agonist with extensive clinical data. Tirzepatide delivers approximately 21% weight loss with a well-characterized safety profile and established clinical protocols. It is the best available incretin therapy today.
Choose Retatrutide if: you are eligible for and interested in clinical trial enrollment, or once it receives FDA approval. Phase 2 data suggests potentially greater weight loss through triple agonism. However, it remains investigational — Phase 3 data, long-term safety, cardiovascular outcomes, and regulatory approval are all pending.
For most patients today, tirzepatide is the appropriate choice. Retatrutide represents the future of incretin therapy, but it is not yet the present.